Development of lung T cell responses in infant respiratory immunity
Development of lung T cell responses in infant respiratory immunity
批准号:
10221314
负责人:
Donna L. Farber
金额:
$74.2万
依托单位国家:
美国
项目类别:
财政年份:
2020
资助国家:
美国
项目状态:
已结题
起止时间:
2020-12-03 至 2022-07-31
关键词:
2019-nCoVAcuteAdultAdult Respiratory Distress SyndromeAffectAneurysmAntibodiesAntibody ResponseAttenuatedBiological AssayBlood specimenBusinessesCOVID-19COVID-19 pandemicCOVID-19 patientCOVID-19 severityCOVID-19 vaccineCOVID-19/ARDSCardiacCardiogenic ShockCardiologyCardiopulmonaryCardiovascular systemCharacteristicsChildChildhoodClinicalClinical DataComplicationCoronaryCoronary arteryCoughingCritical CareDataDecision MakingDevelopmentDiseaseEchocardiographyElderlyEnrollmentEpitopesFatigueFerritinFeverFibrin fragment DFlow CytometryFunctional disorderFutureHealthHospitalsImmuneImmune responseImmunityImmunoglobulin GImmunologicsImmunologistIncidenceIndividualInfantInfectionInflammationInflammatoryInterleukin-6LearningLifeMeasurementMediatingMedical centerMedicineMorbidity - disease rateMucocutaneous Lymph Node SyndromeMultisystem Inflammatory Syndrome in ChildrenMyocardial dysfunctionNeighborhoodsNew YorkNucleocapsid ProteinsOutcomePatientsPediatric cohortPeptidesPopulationPresbyterian ChurchPrevention strategyProspective cohort studyProteinsReadingRecoveryReportingResearchResearch PersonnelRespiratory FailureRespiratory Tract InfectionsRiskSARS-CoV-2 antibodySARS-CoV-2 infectionSARS-CoV-2 positiveSamplingSchoolsShockSymptomsSyndromeT cell responseT-LymphocyteTestingToxic Shock SyndromeVaccinationVasculitisViralVirusWashingtonadaptive immune responseage relatedclinical carecohortcommunity cliniceffector T cellexperiencehigh dimensionalityinfection rateinsightinterdisciplinary approachlung developmentlung injurymortalityneutralizing antibodynovelnovel coronaviruspandemic diseasepediatric patientspediatricianprospectiverespiratoryresponsesevere COVID-19treatment strategy
中文摘要
项目总结
SARS-CoV-2的出现已经导致了一场全球大流行。感染SARS-CoV-2导致
疾病症状的范围从无症状和轻度/自限性疾病到严重疾病
与严重的肺损伤以及高发病率和高死亡率有关。就像所有的个体一样
在免疫上对这种病毒很天真,目前还没有针对SARS的针对性治疗或疫苗-
CoV-2的保护和恢复依赖于我们自己的免疫反应和支持性临床护理。最初,
儿童经历了大部分无症状或轻微的疾病,严重的疾病导致明显的肺部
受伤是一种罕见的情况。然而,一种新的儿童多系统炎症性疾病(MIS-C)与
SARS-CoV-2已成为感染的晚期并发症。患有MISC的儿童通常与
心功能障碍和休克,与川崎病和中毒性休克综合征最为相似。
重要的是,据报道,一些患有MISC的儿童会患上冠状动脉动脉瘤,
发现川崎病的共同之处。与之形成对比的是,儿童中有大量的轻度/自限性疾病。
与SARS-CoV-2相关的过度炎症提示有明显的免疫反应。
此外,早期生命感染的长期影响,特别是对心血管系统的影响
SARS-CoV-2病毒仍不清楚。我们假设儿童的这些不同的临床表现包括
SARS-CoV-2没有出现症状呼吸道感染是由于T细胞反应强劲和增强。这个
这项建议的目的是:1)建立儿科患者队列,用于比较预后和免疫力
儿科新冠肺炎病的所有反应,2)定义儿科免疫反应
SARS-CoV-2及其在临床疾病谱中的不同之处,以及3)定义
与持续不良心脏结局相关的患者特征与患有MIS-C和
儿科新冠肺炎。本项目建议为儿科免疫和长期免疫提供新的见解
采用多学科方法研究SARS-CoV-2感染的并发症
调查人员包括免疫学家、儿科医生和儿科专科医生(心脏病学/重症监护
医学)。这些研究将提供宝贵的见解,有助于指导未来的治疗决策
以及针对儿童的预防策略。
英文摘要
PROJECT SUMMARY
The emergence of SARS-CoV-2 has resulted in a worldwide pandemic. Infection with SARS-CoV-2 causes a
spectrum of disease symptoms ranging from asymptomatic and mild/self-limited disease, to severe disease
associated with significant lung damage and high levels of morbidity and mortality. As all individuals are
immunologically naïve to this virus and there are currently no targeted treatments or vaccines against SARS-
CoV-2, protection and recovery depend on our own immune responses and supportive clinical care. Initially,
children experienced largely asymptomatic or mild disease with severe disease resulting in significant lung
injury a rare occurrence. However, a new multisystem inflammatory disorder in children (MIS-C) related to
SARS-CoV-2 has emerged as a late complication of infection. Children with MIS-C commonly present with
cardiac dysfunction and shock, most closely resembling Kawasaki disease and toxic shock syndrome.
Importantly, some children presenting with MIS-C have been reported to develop coronary artery aneurysms, a
finding common to Kawasaki disease. The significant amount of mild/self-limited disease in children contrasted
with the excessive inflammation associated with SARS-CoV-2 suggests distinct immune responses.
Additionally, the long-term implications, particularly to the cardiovascular system, of early life infection with
SARS-CoV-2 remain unknown. We hypothesize that these distinct clinical manifestations in children, including
lack of symptomatic respiratory infection to SARS-Cov-2 is due to a robust and enhanced T cell response. The
aims of this proposal are to 1) Establish pediatric patient cohorts for comparing outcomes and immune
responses across the spectrum of pediatric COVID-19 disease, 2) Define the pediatric immune response to
SARS-CoV-2 and how it differs across the clinical spectrum of disease, and 3) Define the incidence of and
patient characteristics associated with sustained adverse cardiac outcomes for children with MIS-C and
pediatric COVID-19. This project proposes to provide new insights into the pediatric immune and long-term
complications of SARS-CoV-2 infection by employing a multi-disciplinary approach utilizing a team of
investigators including immunologists, pediatricians, and pediatric subspecialists (cardiology/critical care
medicine). These studies will provide invaluable insight that will help guide future decision making for treatment
and preventative strategies for children.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Training in Cellular, Molecular and Biomedical Studies (CMBS)
-
批准号:10424890
-
项目类别:
-
资助金额:$83.26万
-
财政年份:2022
-
负责人:Donna L. Farber
-
依托单位:
The generation and protective function of lung tissue resident memory T cells following SARS-CoV-2 infection or vaccination
-
批准号:10580806
-
项目类别:
-
资助金额:$87.86万
-
财政年份:2022
-
负责人:Donna L. Farber
-
依托单位:
Evolution of T cell immunity in blood and tissues over childhood
-
批准号:10593160
-
项目类别:
-
资助金额:$80.76万
-
财政年份:2022
-
负责人:Donna L. Farber
-
依托单位:
The generation and protective function of lung tissue resident memory T cells following SARS-CoV-2 infection or vaccination
-
批准号:10467872
-
项目类别:
-
资助金额:$91.64万
-
财政年份:2022
-
负责人:Donna L. Farber
-
依托单位:
Evolution of T cell immunity in blood and tissues over childhood
-
批准号:10435197
-
项目类别:
-
资助金额:$82.09万
-
财政年份:2022
-
负责人:Donna L. Farber
-
依托单位:
Human anti-viral immune responses in tissues and circulation
-
批准号:10201036
-
项目类别:
-
资助金额:$16.2万
-
财政年份:2021
-
负责人:Donna L. Farber
-
依托单位:
Modeling the ecology of tissue-resident T cells
-
批准号:10417226
-
项目类别:
-
资助金额:$99.77万
-
财政年份:2020
-
负责人:Donna L. Farber
-
依托单位:
Modeling the ecology of tissue-resident T cells
-
批准号:10632031
-
项目类别:
-
资助金额:$100.59万
-
财政年份:2020
-
负责人:Donna L. Farber
-
依托单位:
Development of lung T cell responses in infant respiratory immunity
-
批准号:10321807
-
项目类别:
-
资助金额:$77.66万
-
财政年份:2020
-
负责人:Donna L. Farber
-
依托单位:
Modeling the ecology of tissue-resident T cells
-
批准号:10241910
-
项目类别:
-
资助金额:$99.99万
-
财政年份:2020
-
负责人:Donna L. Farber
-
依托单位:
Administrative Core
-
批准号:10594520
-
项目类别:
-
资助金额:$9.21万
-
财政年份:2017
-
负责人:Donna L. Farber
-
依托单位:
Human anti-viral immune responses in tissues and circulation
-
批准号:10419865
-
项目类别:
-
资助金额:$234.35万
-
财政年份:2017
-
负责人:Donna L. Farber
-
依托单位:
Human anti-viral immune responses in tissues and circulation
-
批准号:10594518
-
项目类别:
-
资助金额:$234.35万
-
财政年份:2017
-
负责人:Donna L. Farber
-
依托单位:
Human T cell-mediated immunity to viruses in tissues and circulation
-
批准号:10419870
-
项目类别:
-
资助金额:$29.29万
-
财政年份:2017
-
负责人:Donna L. Farber
-
依托单位:
Administrative Core
-
批准号:10419866
-
项目类别:
-
资助金额:$29.29万
-
财政年份:2017
-
负责人:Donna L. Farber
-
依托单位:
Clinical Core
-
批准号:10419867
-
项目类别:
-
资助金额:$29.29万
-
财政年份:2017
-
负责人:Donna L. Farber
-
依托单位:
Clinical Core
-
批准号:10594521
-
项目类别:
-
资助金额:$26.97万
-
财政年份:2017
-
负责人:Donna L. Farber
-
依托单位:
Human T cell-mediated immunity to viruses in tissues and circulation
-
批准号:10594533
-
项目类别:
-
资助金额:$38.88万
-
财政年份:2017
-
负责人:Donna L. Farber
-
依托单位:
Lung resident niches for memory CD4 T cells
-
批准号:8803453
-
项目类别:
-
资助金额:$39.8万
-
财政年份:2014
-
负责人:Donna L. Farber
-
依托单位:
Lung resident niches for memory CD4 T cells
-
批准号:9188015
-
项目类别:
-
资助金额:$39.8万
-
财政年份:2014
-
负责人:Donna L. Farber
-
依托单位:
海外基金